Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 7 Squamous Cell Carcinoma of Head and Neck 2 Small Cell Lung Carcinoma 2 Sjogren's Syndrome 1 Scleroderma, Systemic 1 Recurrence 1 Psoriasis 1 Ovarian Neoplasms 1 Oropharyngeal Neoplasms 1 Neoplasms 1 Multiple Sclerosis 1 Melanoma 1 Lymphatic Metastasis 1 Lupus Erythematosus, Systemic 1 Lung Neoplasms 1 Inflammatory Bowel Diseases 1 Hematologic Neoplasms 1 Head and Neck Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Dermatomyositis 1 Crohn Disease 1 Colitis, Ulcerative 1 Carcinoma, Squamous Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Bronchogenic 1 Carcinoma 1 Bronchial Neoplasms 1 Autoimmune Diseases 1 Arthritis, Rheumatoid 1 Arthritis, Psoriatic 1

Interventions

Cyclophosphamide 26 fludarabine 18 Dexamethasone 17 pembrolizumab 12 Rituximab 11 Etoposide 10 venetoclax 9 pomalidomide 9 Gemcitabine 9 fludarabine phosphate 7 daratumumab 7 Lenalidomide 7 Bortezomib 7 carfilzomib 6 obinutuzumab 5 glofitamab 5 Vincristine 5 Temozolomide 5 Prednisone 5 Nivolumab 5 Immunotherapy, Adoptive 5 Cisplatin 5 Calcium Dobesilate 5 selinexor 4 cemiplimab 4 Doxorubicin 4 Cytarabine 4 Carboplatin 4 zanubrutinib 3 ruxolitinib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × Platinum Compounds × 90 days × Clear all

NCT07340164 2026-04-20

TROY

Yonsei University

Phase 2 Recruiting

Ovarian Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡